Scott Requadt's Net Worth
$9.27 Million
Who is Scott Requadt?
Scott Requadt has an estimated net worth of $9.27 Million. This is based on reported shares across multiple companies, which include VBI Vaccines Inc/BC, Talaris Therapeutics, Inc., ESSA Pharma Inc., Entasis Therapeutics Holdings Inc., AVROBIO, Inc., and Forty Seven, Inc..
SEC CIK
Scott Requadt's CIK is 0001664852
Past Insider Trading and Trends
2022 was Scott Requadt's most active year for acquiring shares with 8 total transactions. Scott Requadt's most active month to acquire stocks was the month of June. 2023 was Scott Requadt's most active year for disposing of shares, totalling 3 transactions. Scott Requadt's most active month to dispose stocks was the month of May. 2022 saw Scott Requadt paying a total of $239,360.36 for 659,948 shares, this is the most they've acquired in one year. In 2023 Scott Requadt cashed out on 41,788 shares for a total of $36,300.88, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Entasis Therapeutics Holdings Inc. No price found
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +204.79% | 1.55M |
$15.00 |
—
| 2.31M |
Sep 28
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Forty Seven, Inc. No price found
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +406.71% | 3.82M |
$16.00 |
—
| 4.76M |
Jul 2
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
VBI Vaccines Inc/BC (VBIV) No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 31
| |||
Form 4
| +50.00% | 12.5K |
—
|
—
| 37.5K |
Jun 14
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 23
| |||
Form 4
| +100.00% | 12.5K |
—
|
—
| 25K |
Jun 14
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 31
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Talaris Therapeutics, Inc. (TRML) Snapshot price: $16.11
Chief Executive Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -2.00% | -11.79K |
$3.08 | -$36,300.88 | 578.4K |
Jul 3
| |||
Form 4
| +0.00% | 4 |
$0.87 | $3.47 | 590.19K |
Dec 30 - Feb 1
| |||
Form 4
| +15.68% | 80K |
—
|
—
| 590.19K |
Sep 10
| |||
Form 4
| +8.39% | 39.38K |
$4.25 | $167,373.50 | 508.68K |
Jul 29
| |||
Form 4
| +1.87% | 8.62K |
$4.24 | $36,571.22 | 469.3K |
Jul 26 - Jul 28
| |||
Form 4
| +2.09% | 9.44K |
$3.75 | $35,412.17 | 460.68K |
Jul 22
| |||
Form 4
| +0.33% | 1.47K |
$13.00 | $19,110.00 | 451.24K |
Dec 31 - Feb 1
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
ESSA Pharma Inc. (EPIX) Snapshot price: $5.9
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 25
| |||
Form 4
| -50.00% | -30.00K |
—
|
—
| 30K |
Oct 30 - Nov 6
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 29
| |||
Form 4/A
|
—
|
0
|
—
|
—
|
0
|
Dec 11
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 11
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||